Your trusted source for investing success

Tag: astrazeneca

Myriad’s BRACAnalysis CDx® Test Successfully Identified Metastatic Breast Cancer Patients with Improved Outcomes from AstraZeneca’s PARP Inhibitor, Olaparib

Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced new findings from the OlympiAD study that show its BRACAnalysis CDx®  test successfully identified patients with HER2-negative metastatic breast cancer who have BRCA mutations and who had improved response with Lynparza (olaparib), AstraZeneca’s PARP inhibitor.

The high

DelMar Pharmaceuticals Announces Dosing of the First Patient in Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)

DelMar Pharmaceuticals Announces Dosing of the First Patient in Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)

DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced today that patient dosing has commenced in a Phase 2 clinical study of its investigational drug VAL-083 (dianhydrogalactitol) for MGMT-unmethylated Avastin®(bevacizumab)-naïve recurrent glioblastoma.

TapImmune Announces Progress In Its Phase 2 Ovarian Cancer Clinical Trial

TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment of cancer and metastatic disease, today announced that Memorial Sloan Kettering Cancer Center (MSKCC) successfully completed the first safety cohort in its Phase 2 ovarian cancer study. The study is

How Personalized Medicine Can Change Your Investment Strategy

How Personalized Medicine Can Change Your Investment Strategy

Pharmaceutical companies have developed numerous strategies to counter the patent cliff. One such tactic? Capitalizing on the personalized medicine market. As it turns out, this niche market is less vulnerable to the patent cliff—which may make it attractive to pharmaceutical companies and investors alike.

Enter Your Log In Credentials
×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network